Survey assessment on pediatricians’ attitudes on head lice management

Claudia Fancelli, Manuela Prato, Carlotta Montagnani, Monica Pierattelli, Paolo Becherucci, Elena Chiappini, Maurizio de Martino and Luisa Galli*

Abstract

Background: Pediculosis capitis is a worldwide health problem. One of the most important factor in effective head lice eradication is to ensure that infestation is adequately recognized and treated. Our survey investigated the knowledge and practice among primary care Italian pediatricians regarding to the prevention and treatment of head lice.

Methods: The questionnaire was distributed to all the pediatricians registered at the Annual Congress of Practice in Pediatrics held in Florence, Italy, November 11–12, 2011. It includes 10 questions in a multiple choice format, and one answer for each question was provided. The questionnaire was conceived by pediatricians at the Infectious Disease Unit of the Department of Science for the Health of Woman and Child, University of Florence. Questions were designed according to the guidelines by the Italian Pediatric Society (SIP), and international guidelines, such as the Centers for Disease Control and Prevention (CDC), and the American Academy of Pediatrics (AAP).

Results: Overall, 364/600 pediatricians (60.7% of physicians registered to the Congress) returned the questionnaire. The majority of them (232/364; 63.7%) believe that parents consult their primary care pediatrician only after the failure of other "remedies". Mostly, they prescribe Malathion (116/364, 31.8%) as first line treatment. Two-hundred-forty-three (66.7%) of participants consider creams, foams and gels the most effective formulations. Two-hundred-sixty-two of pediatricians interviewed (72.0%) suggest to repeat the treatment after one week, 37/364 (10.2%) after two weeks. The majority of the pediatricians interviewed reported that recurrences occur in less than 30% of cases (279/364; 76.6%). In their own opinion, most of recurrences are the consequence of a reinfection in the community (259/264; 77%). Three-hundred-thirty-four (91.7%) of them have never prescribed oral therapy for the treatment of head lice. Finally, 289/364 (79.4%) pediatricians believe that no product is effective for prevention.

Conclusions: This is the first study that investigates the clinical practice of family pediatricians about the management and treatment of head lice globally, the Italian pediatricians surveyed proved to be quite informed on the head lice management. However, even in a country where pediatric assistance is free for everybody, a considerable proportion of parents do not seek advice to their own family pediatrician. Therefore, educations of parents, other than continuous updating of pediatricians, may contribute to a better management of head lice in the community.

Keywords: Head lice, Infestation, Children, Pediatrics
Background
Pediculosis capitis is a worldwide health problem. In high resource countries, the overall prevalence of head lice infestation is 1-3%, although there is a high variability among countries. In Italy, a 2003 report estimated an incidence of 2-3% in general population [1], while in other European countries prevalence ranges between 0.8 and 9.9% [2-7]. In the USA estimates range from 6 to 12 million cases of infestation per year [8]. Although the infestation is characterized by a low morbidity, it may cause a considerable social distress in terms of discomfort to the child, absences from school and expenses incurred for treatment. Conventional topical pediculicides remain the most commonly used form of treatment globally. However, in the last 10 years, conventional therapy with topical pediculicides is increasingly associated with treatment failure and the emergence of resistance [9]. Many factors are hypothesized to cause recidives: incorrect use of pediculicides regarding to the dose and duration of the treatment, type of formulation, residual pediculicide effect, incorrect prophylaxis or intrinsic genetic resistance in lice [10-13]. However, a considerable proportion of recidives are a result of incorrect use of treatment rather than to intrinsic resistance in lice [14]. Therefore, the most important factor in effective head lice eradication is to ensure that infestation is adequately recognized and treated. Our survey investigated the knowledge and practice among primary care Italian pediatricians regarding to the prevention and treatment of head lice.

Materials and methods
The questionnaire was distributed to all pediatricians registered at the Annual Congress of Practice in Pediatrics held in Florence, Italy, November 11–12, 2011. This meeting is one of the most important national meeting and about 600 primary care pediatricians attend this meeting every year from all over the country.

A self-administered, anonymous questionnaire was distributed to all the pediatricians at the Congress registration desk. Overall, 600 questionnaires were distributed. The survey was administered in Italian and translated into English for publication. The English version of the questionnaire is enclosed in Additional file 1. It includes 10 questions in a multiple choice format. One answer for each question was provided. The questionnaire was conceived by pediatricians at the Infectious Disease Unit of the Department of Science for the Health of Woman and Child, University of Florence. Questions were designed according to the guidelines by the Italian Pediatric Society (SIP) [15], and international guidelines, such as the Centers for Disease Control and Prevention (CDC) [16], and the American Academy of Pediatrics (AAP) [17]. Participants were asked what kind of topical treatment they would first administer in head lice and what kind of treatment they believe to be more safe and effective in children <2 years. They were also asked to specify whether and when pediculicides treatment would be repeated, which formulation would be more effective among shampoos, powders, creams, gels, foams and sprays and the most effective attitude in preventing transmission. Final questions explored the participants’ experience and opinion towards head lice recurrence and their own attitude in case of reinfection and infestation recurrence, including administration of oral therapy.

Results
Overall, 364 pediatricians (60.7% of physicians registered to the Congress) returned the questionnaire. The majority of them (232/364; 63.7%) believe that parents ask to their own friends, their relatives or the pharmacist or reading news on Internet about the management of head lice, rather than consulting their primary care pediatrician. Moreover, we investigated the attitude towards the prescription of pediculocides in all age groups and in children younger than 2 years. Results are shown in Table 1.

Two-hundred-forty-three (66.7%) of participants consider creams, foams and gels the most effective formulations. The remaining proportion of pediatricians believed that the most effective formulations are shampoos (72/364; 19.7%) or sprays (25/364; 6.8%) or powders (5/364; 1.4%). Two-hundred-sixty-two of pediatricians interviewed (72.0%) suggest to repeat the treatment after one week, 37/364 (10.2%) after two weeks. A minority of them (58/364; 15.9%) does not always repeat the treatment and a very low percentage (4/364; 1.1%) repeat the treatment after 4 weeks.

Moreover, the majority of the pediatricians interviewed reported that recurrences occur in less than 30% of cases (279/364; 76.6%). In their own opinion, most of recurrences are the consequence of a reinfection in the community (259/264; 77%), rather than lice intrinsic resistance to pediculicides (22/364; 7%) or the incorrect use of these products by parents (45/364; 14%). The pediatricians attitude toward the repetition of a second full course of treatment in case of recurrence/reinfestation is shown in Table 2. Three-hundred-thirty-four (91.7%) of them have never prescribed oral therapy for the treatment of head lice. Twenty-four (6.5%) prescribed sulfamethoxazole-trimethoprim; no-one has suggested treatment with oral ivermectine. Finally, we investigated the attitude towards prevention methods. Two-hundred-eighty-nine (79.4%) pediatricians believe that no product is effective for prevention, while a minority of them suggested preventive therapy with topical pediculicides [19/364 (5.2%)], the disinfection of school and home environments [40/364 (10.9%)], and only 6/364 (1.6%) the use of hats and headgear.

Discussion
This is the first study that investigates the clinical practice of family pediatricians about the management
and treatment of head lice. Until now, several studies have focused on parental knowledges and attitudes [18-20]. Our survey agrees with all these studies showing that parents often seek advice firstly from the apothecary, or relatives, or friends, and only after a failure from a physician.

Proper education of parents is an essential component of the treatment of head lice, as well as clear treatment plans. Three options are currently described for the treatment of head lice: topical pediculocides, use of the comb and oral therapy [15-17]. The preferred topical pediculocides among these available in Italy are permethrin and other pyrethroids, synergized pyrethrins, and malathion. In our survey, we founded that only 10.4% of the interviewed pediatricians choices permethrin as first line treatment in head lice, while about one third of pediatricians choices pirethroids and synergized pirethrins and another third of them suggests 0.5% malathion. At the time of our survey (2011), US and Italian guidelines suggested

| First line prescription treatment | Treatment in children <2 years |
|----------------------------------|-------------------------------|
| Drugs                            | N (%)                         |
| Permethrin                       | 38/364 (10.4)                 |
| Other pirethroids and natural synergized pirethrins | 13/38 (34.2) |
| Malathion                        | 3/38 (0.8)                    |
| Natural oils                     | 1/38 (0.3)                    |
| Dimeticone                       | 4/38 (10.5)                   |
| Manual removal                   | 11/38 (26.9)                  |
| I don’t know                     | 4/38 (10.5)                   |
| Other pirethroids and natural synergized pirethrins | 2/38 (0.5) |
| Malathion                        | 107/364 (29.4)                |
| Natural oils                     | 3/107 (2.8)                   |
| Dimeticone                       | 51/107 (47.7)                 |
| Manual removal                   | 0                             |
| I don’t know                     | 32/107 (29.9)                 |
| Malathion                        | 116/364 (31.8)                |
| Other pirethroids and natural synergized pirethrins | 12/116 (10.3) |
| Malathion                        | 1/116 (0.9)                   |
| Natural oils                     | 42/116 (36.2)                 |
| Dimeticone                       | 5/116 (4.3)                   |
| Manual removal                   | 31/116 (26.7)                 |
| I don’t know                     | 15/116 (12.9)                 |
| Other pirethroids and natural synergized pirethrins | 2/107 (1.9) |
| Malathion                        | 76/364 (20.9)                 |
| Natural oils                     | 1/76 (1.3)                    |
| Dimeticone                       | 4/76 (5.6)                    |
| Manual removal                   | 31/76 (40.5)                  |
| I don’t know                     | 3/76 (3.9)                    |
| Malathion                        | 9/364 (2.5)                   |
| Natural oils                     | 2/76 (2.6)                    |
| Dimeticone                       | 0                             |
| Manual removal                   | 0                             |
| I don’t know                     | 0                             |
| Other pirethroids and natural synergized pirethrins | 0 |
| Malathion                        | 7/9 (77.8)                    |
| Natural oils                     | 0                             |
| Dimeticone                       | 0                             |
| Manual removal                   | 2/9 (22.2)                    |

Table 1 Lice treatment in children < 2 years of age according to the first line treatment chosen
1% permethrin as one of the treatments of choice for head lice because of its efficacy and lack of toxicity [21]. However, resistance to 1% permethrin is increasingly been reported [22-24]. Also other pirethroids (es. Phenotrin) and pirethrins synergized, which are pyrethrins combined with piperonyl butoxide, were considered as first choice by US and Italian guidelines. As regards to malathion, both the Italian and the US guidelines, published in 2010 and therefore available at the moment of our survey, suggested it as second choice, because of the odor, the flammability, and the risk of respiratory depression if ingested [15-17]. Instead, the more recent 2012 UK guidelines [25] recommend malathion as first line treatment. It is of note that there are some differences between the European and the US formulation. First of all, the European formulation is in an aqueous basis (even with a minimum alcohol content), whereas the US formulation is more flammable, since it contains 78% isopropyl alcohol. Moreover, malathion seems to have less efficacy in Europe than in the US, probably because its continuous use in Europe during the past 30 years, whereas in US it was withdrawn in 1990 and again in 1994 and definitively reintroduced in 1999. Moreover, the formulation available only in the US (Ovide®), contains isopropanol and terpenes, which seems to have its own pediculocidal effects [26]. The results of our survey clearly show the need of frequent updating and spreading at least every 2 years national guidelines.

A further finding of our survey is that nearly 50% of pediatricians who prescribe a conventional topical pediculicide as first line therapy, administrate the same treatment in children under 24 months of age. As a matter of fact, about 40% of pediatricians choose malathion as first line treatment, and suggest this product also in children under 24 months. In general, conventional pediculicides are not recommended in children younger than 6 years, because there are not enough studies to support its safety, and it is moreover contraindicated in children younger than 2 years [21].

It is also of note that about one fifth of pediatricians prescribe dimethicone as first line treatment and only 40.1% prescribe it in children under 24 months. In fact, in this age group, dimethicone could be an excellent therapeutic tool, since it is odorless, non-toxic and generally well tolerated by children from 6 months of age [15-17]. It acts by coating the lice and causing suffocation and has neither pediculocide nor ovocidal activity. A study in the United Kingdom reported a cure rate of nearly 70% [30], a study in Turkey reported cure rates of 92% [31], and another large randomized trial conducted in Brazil [32], in which a different formulation of dimethicone was used (92% dimethicone), reported a 97% cure rate. Maybe it is a new product, there are few studies (all from the same authors), and Italian pediatricians

| Table 2 Percentage of recidives/reinfestations reported by pediatricians according to the first line prescription treatment suggested, the second cicle of treatment proposed, and the time range recommended for the repetition of the treatment |
|-------------------------------------------------|---------------------------------|-----------------|-----------------|
| First line prescription treatment                | Percentage of recidives/reinfestations |
| Permethrin (38/364)                              | Rarely or less than 10%            | 22/38 (57.9)    | 14/38 (36.8)    |
| Other pirethroids and natural pirethrins synergized (107/364) | 71/107 (66.3)                      | 34/107 (31.8)   | 2/107 (0.0)     |
| Malathion (116/364)                              | 76/116 (65.5)                      | 39/116 (33.6)   | 1/116 (0.0)     |
| Natural oils (9/364)                             | 9/9 (100)                          | 0               |
| Dimeticone (76/364)                              | 49/76 (64.5)                       | 24/76 (31.6)    | 3/76 (0.0)      |
| I don't know (5/364)                             | 143/220 (71.5)                     | 72/220 (32.7)   | 5/220 (0.0)     |
| The second cicle of treatment suggested in case of recidive/reinfestations | Repetition of a second complete cycle of treatment of the same class as that used previously (220/364) | 131/131 (64.95) | 44/131 (33.6)   | 2/131(0.0) |
| Time range recommended for the repetition of the treatment | No, not always. It depends on the product used (58/364) | 44/58 (75.8)    | 14/58 (24.1)    | 0 |
| After 1 week (262/364)                           | 164/262 (62.6)                     | 93/262 (35.5)   | 5/262 (0.0)     |
| After 2 weeks (37/364)                           | 26/37 (70.3)                       | 10/37 (27.0)    | 1/37 (0.0)      |
| After 4 weeks (4/364)                            | 2/4 (50.0)                         | 0               |

Fancelli et al. Italian Journal of Pediatrics 2013, 39:62
http://www.ijponline.net/content/39/1/62
of lice resistance to topical pediculicides in the last years to pediculocides. Several studies report an increasing rate (lice reacquired after treatment); and resistance of lice adequate dosis or duration of treatment; re-infestation adherence of the patient to the treatment protocol; in-pediculocides may have several causes, such as: lack of the persistence of living head lice after the use of treatment (two applications of treatment 7 days apart) should be considered a sign of treatment failure [25].

Finally, very few (3%) pediatricians suggest a treatment with oils or other herbal products: their safety and efficacy are currently unknown and they are not recommended [21].

Our survey also shows that oral pediculicides (Ivermectin and Sulfamethoxazole-Trimethoprim) are, correctly, very rarely prescribed. Recently (February 2012), topical ivermectin lotion (Sklice®) was approved by the FDA. It is indicated for the treatment of head lice in children aged 6 months and older: it shows good therapeutic perspectives [34,35].

Another result of our study is that the majority of pediatrician interviewed (72%) recommend routine retreatment for all topical pediculocides, preferably on day 7–9, as well as many experts suggest [21]. Improper timing of second application of pediculicides should be considered an important cause of treatment failure.

In literature there is a lack of data about the real incidence of treatment failure in children. The majority of pediatricians interviewed (65%) report a frequency of 10% or less of short term recidives (<2 months from treatment), while nearly one third reports a frequency rate between 30 and 50%. The majority of them believe that recidives are attributable to a re-infestation in the childhood community. More important, the ongoing presence of nits or itch is not a sign of treatment failure, since nits could be not alived. Only the finding of live lice, using a detection comb, two or three days after completing a course treatment (two applications of treatment 7 days apart) should be considered a sign of treatment failure [25].

The persistence of living head lice after the use of pediculocides may have several causes, such as: lack of adherence of the patient to the treatment protocol; inadequate dosis or duration of treatment; re-infestation (lice reacquired after treatment); and resistance of lice to pediculocides. Several studies report an increasing rate of lice resistance to topical pediculicides in the last years [13,36,37]. There are three main patterns of resistance: genetic resistance (the presence of polymorphisms in genes associated with resistance); clinical resistance (persistence of live lice after a cycle of application); parasitologic resistance (in vivo resistance of lice to pediculocide compounds). As Durand R describes in a recent review, permethrin-resistant phenotypes are mostly associated with a recessive kdr trait, while no genetical mechanism has been formally reported for malathion [26]. Now, resistance rather than a lack of compliance with treatment should be considered the main cause of a treatment failure [38]. Currently, several strategies have been proposed to overcome a possible treatment failure. One of the strategies is the application of a product for a full-course treatment and, in case of failure, the use pediculocide with a different resistance profile [17,25]. Only 37% of pediatricians interviewed used this type of therapeutic approach. Probably, the restriction of pediculocides availability only with medical prescription, the administration of these drugs at the right dose and with a correct timing may help in prevent treatment failure.

The main limit of our study is that over 40% of pediatricians attending the conference did not respond to our questionnaire and non-responders may be less updated on national guidelines as compared to responder’s pediatricians. Globally, the Italian pediatricians surveyed proved to be quite informed on head lice management. Moreover, pediatricians should advise parents that head lice infestation should be diagnosed and treated under the supervision of a physician. In fact, proper education of parents, other than continuous updating of pediatricians, may contribute to a better management of head lice in the community.

Additional file

Additional file 1: Questionnaire on the management and treatment of head lice for the pediatrician.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
CF, MP, LG, MdM conceived of the study, performed the statistical analysis and drafted the manuscript. MP, PB, CM, EC participated in the design of the study and helped to draft the manuscript. All authors read and approved the manuscript.

Received: 27 April 2013 Accepted: 15 September 2013 Published: 3 October 2013

References
1. Gelmetti C, Veraldi S, Scanni G: Head lice: proposal for therapeutic guidelines. Italian J Dermat Vener 2004, 139:1–4.
2. Ciftci IH, Karaca S, Dogruo O: Prevalence of pediculosis and scabies in preschool nursery children of Afyon, Turkey. Korean J Parasitol 2006, 44:95–98.
3. Kokturk A, Baz K, Bugdayci R: The prevalence of pediculosis capitis in schoolchildren in Mersin, Turkey. Int J Dermatol 2003, 42:694–698.
17. Pickering LK, Baker CJ, Kimberlin DW, American Academy of Pediatrics:

20. Silva L, de Aguiar AR:

30. Burgess IF, Brown C, Lee PN:

31. Kurt O, Balcioglu IC, Burgess IF:

13. Bartels CL, Peterson KE, Taylor KL:

12. Burgess I:

How to advise a patient when over the counter products have failed. BMJ 2003, 326:1257.

14. Maunder JW: Strategic aspects of insecticide resistance in head lice. J R Soc Health 1991, 111:24–26.

15. SP, ADQI, SEDMAST: Guidelines for the diagnosis and treatment of head lice, 2010.

16. Centers for Disease Control and Prevention (CDC): Head lice, 2010. On www.cdc.gov/parasites/lice/head.

17. Pickering LK, Baker CJ, Kimberlin DW, American Academy of Paediatrics (AAP): Pediculosis Capitis. In Red Book: 2009 Report of The Committee of Infectious Diseases. 28th edition. Edited by Pickering LK. Elk Grove Village; 2009:495–497.

18. Douglouki A: Parental attitudes towards head lice infestations in Greece. Int J Dermatol 2011, 50:689–692.

19. Counahan ML, Andrews RM, Weld H: What parents in Australia know and do about head lice. Rural Remote Health 2007, 7:687.

20. Silva L, de Aguilar AR: Survey assessment of parental perceptions regarding head lice. Int J Dermatol 2008, 47:249–255.

21. Frankowski BL, Bocchini JA Jr, Council on School Health and Committee on Infectious Diseases: Head lice, Pediatrics 2010, 126:392.

22. Meinking TL, Serrano L, Hard B: Clinical update on resistance and treatment of pediculosis capitis in paediatrics. J Pediatr Health Care 2012, 26:451–461.

23. Mumcuoglu KY, Hemingway J, Miller J: Permethrin resistance in the head louse Pediculus Capitis in Israel. Med Vet Entomol 1995, 3:30–32.

24. Pollack RJ, Kiszewski A, Armstrong P: Differential Permethrin susceptibility of head lice sampled in the United States and Borneo. Arch Pediatr Adolesc Med 1999, 153:869–873.

25. Broad P, Carney J, Gee S, Health Protection Agency North West: The prevention, identification and management of head lice infestation in the community, 2012. On www.hpa.org.uk, review date November.

26. Durand R, Bourvresse S, Berdiane Z: Insecticide resistance in head lice: clinical, parasitological and genetic aspects. Clin Microbiol Infect 2012, 18:338–344.

27. Roberts RJ: Head lice. N Engl J Med 2002, 346:1645–1650.

28. Frydenberg A, Starr M: Head lice. Aust Fam Physician 2003, 32:607–611.

29. Alexander KC, Fong JHS, Pinto-Rojas A: Pediculosis Capitis. J Pediatr Health Care 2005, 19:369–373.

30. Burgess IF, Brown C, Lee PN: Treatment of head louse infestation with 4% dimethicone lotion: randomized controlled equivalence trial. BMJ 2005, 330:4123.

31. Kurt O, Balcioglu IC, Burgess IF: Treatment of head lice with dimethicone 4% lotion: comparison of two formulations in a randomised controlled trial in rural Turkey. BMC Public Health 2009, 9:441.

32. Heukelbach J, Pilger D, Oliveira FA: A highly efficacious pediculicide based on dimethicone: randomised observer blinded trial. BMC Infect Dis 2008, 8:115.

33. Meinking TL, Clineschmidt CM, Chen C: An observer-blinding study of 1% permethrin crème rinse with and without adjunctive combing in patients with head lice. J Pediatr 2002, 141:665–670.

34. Eisenhowe C, Farrington EA: Advancements in the treatment of head lice in pediatrics. J Pediatr Health Care 2012, 26:451–461.